DayTwo is the leading Microbiome-Based Precision Medicine company, developing personalized nutrition, diagnostic, and therapeutic solutions using artificial intelligence and machine learning. DayTwo has the largest full-shotgun database of the gut-microbiome in the world. The database is the foundation for the DayTwo Human Discovery Platform™ to identify precision medicine therapies, diagnostics, and care solutions for metabolic and other diseases. Initial product enables glycemic-control helping type II diabetes patients to balance their blood sugar-levels personalized to the subject’s clinical and personal traits.